Aug 08, 2024 / 10:30AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Q1 FY25 earnings conference call of Alembic Pharmaceuticals Limited. We have with us today Mr. Pranav Amin, Managing Director; Mr. Shaunak Amin , Managing Director; Mr. R.K. Baheti, Director, Finance and CFO; Mr. Ajay Kumar Desai, Senior VP Finance.
As a reminder, this conference call as only for analytics and institutional investors (Operator Instructions) Please note that this conference is being recorded, and I now hand the conference over to Mr. R.K. Baheti. Thank you, and over to you, sir.
R. K. Baheti - Alembic Pharmaceuticals Limited - Director - Finance & CFO
Thanks. Good evening, everyone. Thank you all for joining our first quarter results for FY24/'25. I'm sure you would have received the results. However, let me briefly take you through the numbers. During the quarter, our total revenue grew by 5% to INR 1,562 crore. EBITDA at INR 239 crore is about 15% of sales and grew by 14%. Net profit grew by 12% to INR 135 crore comparing the results corresponding quarter of last year.
Q1 2025 Alembic Pharmaceuticals Ltd Earnings Call Transcript
Aug 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers